<SEC-DOCUMENT>0001415889-25-002366.txt : 20250130
<SEC-HEADER>0001415889-25-002366.hdr.sgml : 20250130
<ACCEPTANCE-DATETIME>20250130162719
ACCESSION NUMBER:		0001415889-25-002366
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250130
FILED AS OF DATE:		20250130
DATE AS OF CHANGE:		20250130

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Brush James
		CENTRAL INDEX KEY:			0001865123
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42490
		FILM NUMBER:		25574104

	MAIL ADDRESS:	
		STREET 1:		C/O AMUNIX PHARMACEUTICALS, INC.
		STREET 2:		2 TOWER PLACE, #1100
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Maze Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001842295
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508505070

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BOULEVARD, SUITE 300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3-01302025_090115.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-01-30</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001842295</issuerCik>
        <issuerName>Maze Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>MAZE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001865123</rptOwnerCik>
            <rptOwnerName>Brush James</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MAZE THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>171 OYSTER POINT BOULEVARD, SUITE 300</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series D Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>12148191</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Frazier Life Sciences Public Fund, L.P.</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Series D Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>3583732</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Frazier Life Sciences Public Overage Fund, L.P.</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Pursuant to the Issuer's Restated Certificate of Incorporation, each share of Series D Convertible Preferred Stock may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock shall automatically convert into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.</footnote>
        <footnote id="F2">These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.   FHMLSP, L.P., FHMLSP, L.L.C. and the reporting person each disclaim beneficial ownership of the shares held by Frazier Life Sciences Public Fund L.P., except to the extent of their respective pecuniary interests therein, if any.</footnote>
        <footnote id="F3">These shares are held directly by Frazier Life Sciences Public Overage Fund L.P. The general partner of Frazier Life Sciences Public Overage Fund L.P. is FHMLSP Overage, L.P. and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., and the reporting person each disclaim beneficial ownership of the shares held by Frazier Life Sciences Public Overage Fund L.P., except to the extent of their respective pecuniary interests therein, if any.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Courtney Phillips, as attorney-in-fact</signatureName>
        <signatureDate>2025-01-30</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ex24-01302025_090115.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex24-01302025_090115.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px"><br></p>
<p style="margin:0px; font-size:11pt" align="center"><b>LIMITED POWER OF ATTORNEY</b></p>
<p style="margin:0px" align="center"><br></p>
<p style="margin:0px; text-indent:48px; font-size:11pt" align="justify">The undersigned hereby constitutes and appoints Jason Coloma, Courtney Phillips, and Amy Bachrodt (each, an <font style="font-family:Arial Unicode MS,Times New Roman">&ldquo;</font><b><i>Attorney-in-Fact</i></b><font style="font-family:Arial Unicode MS,Times New Roman">&rdquo;</font>), as long as such individual is providing services to Maze Therapeutics, Inc., a Delaware corporation (the <font style="font-family:Arial Unicode MS,Times New Roman">&ldquo;</font><b><i>Company</i></b><font style="font-family:Arial Unicode MS,Times New Roman">&rdquo;</font>), acting individually, as the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s true and lawful attorney-in-fact to:</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:72px; font-size:11pt; float:left">(1)</p>
<p style="margin:0px; padding-left:72px; text-indent:-2px; font-size:11pt" align="justify">execute for and on behalf of the undersigned, in the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s capacity as an officer and/or director of the Company, Forms 3, 4, and 5, and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 (as amended, the <font style="font-family:Arial Unicode MS,Times New Roman">&ldquo;</font><b><i>Exchange Act</i></b><font style="font-family:Arial Unicode MS,Times New Roman">&rdquo;</font>), and the rules and regulations thereunder;</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:72px; font-size:11pt; float:left">(2)</p>
<p style="margin:0px; padding-left:72px; text-indent:-2px; font-size:11pt" align="justify">do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4, and 5, and any amendments thereto, and file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority, if required; and</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:72px; font-size:11pt; float:left">(3)</p>
<p style="margin:0px; padding-left:72px; text-indent:-2px; font-size:11pt" align="justify">take any other action of any type whatsoever in connection with the foregoing that, in the opinion of the Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the Attorney-in-Fact may approve in the Attorney-in-Fact<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s discretion.</p>
<p style="margin:0px; clear:left" align="justify"><br></p>
<p style="margin:0px; text-indent:48px; font-size:11pt" align="justify">The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that the Attorney-in-Fact, or the Attorney-in-Fact<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. &nbsp;The undersigned acknowledges that the foregoing Attorney-in-Fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s responsibilities to comply with Section 16 of the Exchange Act.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:47.933px; font-size:11pt" align="justify">The undersigned agrees that the Attorney-in-Fact may rely entirely on information furnished orally or in writing by the undersigned to the Attorney-in-Fact. &nbsp;The undersigned also agrees to indemnify and hold harmless the Company and the Attorney-in-Fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to the Attorney-in-Fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4, or 5 (including amendments thereto) and agrees to reimburse the Company and the Attorney-in-Fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:48px; font-size:11pt" align="justify">This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned<font style="font-family:Arial Unicode MS,Times New Roman">&rsquo;</font>s holdings of, and transactions in securities issued by, the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.</p>
<p style="margin:0px" align="justify"><br></p>
<p style="margin:0px; text-indent:47.933px; font-size:11pt" align="justify"><b>IN WITNESS WHEREOF</b>, the undersigned has caused this Power of Attorney to be executed as of this 2<sup>nd</sup> day of December, 2024.</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:342px; width:384px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:342px; text-indent:-2px; font-size:11pt"><u>/s/ James Brush</u></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:342px; width:384px; font-size:11pt; clear:left; float:left">Name:</p>
<p style="margin:0px; padding-left:342px; text-indent:-2px; font-size:11pt">James Brush</p>
<p style="margin:0px; clear:left"><br></p>
<p style="margin:0px"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
